Current challenges in designing GBM trials for immunotherapy

Journal of Neuro-Oncology

Volumn 123, Issue 3, 2015, Pages 331-337

  Weathers, Shiao Pei ^a   Gilbert, Mark R ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Glioblastoma; Immune checkpoint inhibitors; Immunotherapy; Vaccines; Virotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD133 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PEPTIDE VACCINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RINDOPEPIMUT; STAT3 PROTEIN; TEMOZOLOMIDE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ASEPTIC MENINGITIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL (TOPIC); COLITIS; DENDRITIC CELL; DIARRHEA; DOSE CALCULATION; DRUG TARGETING; GLIOBLASTOMA; GUILLAIN BARRE SYNDROME; HUMAN; HYPOPHYSITIS; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOBIOLOGY; IMMUNOMODULATION; LIVER DISEASE; LYMPHOCYTE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTATIC MELANOMA; METHODOLOGY; MYELITIS; MYOSITIS; NEUROMUSCULAR JUNCTION DISORDER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SARCOIDOSIS; SKIN DISEASE; T LYMPHOCYTE; TEMPORAL ARTERITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VASCULITIS; BRAIN NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; STANDARDS;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; RESEARCH DESIGN;

EID: 84937434464     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1716-2     Document Type: Review

References (55)

1. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
2. Gilbert MR et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091
3. Barker CF, Billingham RE (1977) Immunologically privileged sites. Adv Immunol 25:1–54
4. Jackson CM, Lim M, Drake CG (2014) Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 20(14):3651–3659
5. Fabry Z, Raine CS, Hart MN (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 15(5):218–224
6. Galea I, Bechmann I, Perry VH (2007) What is immune privilege (not)? Trends Immunol 28(1):12–18
7. Dunn GP, Dunn IF, Curry WT (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7:12
8. Bullard DE et al (1986) Immunobiology of human gliomas. Semin Oncol 13(1):94–109
9. Owens T et al (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today 15(12):566–571
10. Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61(4):738–743
11. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10(8):580–593
12. Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958–6962
13. Brooks WH et al (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors characterization of a humoral immunosuppressive factor. J Exp Med 136(6):1631–1647
14. Wrann M et al (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6(6):1633–1636
15. Munn DH, Mellor AL (2004) IDO and tolerance to tumors. Trends Mol Med 10(1):15–18
16. Platten M, Wick W, Weller M (2001) Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52(4):401–410
17. Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12(10):370–374
18. Tada M et al (1993) Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)). J Neurooncol 16(1):25–34
19. Charles NA et al (2011) The brain tumor microenvironment. Glia 59(8):1169–1180
20. Heimberger AB et al (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50(1):158–164 discussion 164–6
21. Wheeler CJ et al (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10(16):5316–5326
22. Yu JS et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64(14):4973–4979
23. Liau LM et al (2000) Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg Focus 9(6):e8
24. Wong AJ et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89(7):2965–2969
25. Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28(31):4722–4729
26. Sampson JH et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13(3):324–333
27. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281
28. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
29. Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526
30. Lebbe C et al (2010) Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial. Annu Oncol 21:401
31. Schartz NE et al (2010) Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20(3):247–250
32. Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158–2167
33. Grauer OM et al (2007) CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121(1):95–105
34. Jiang H et al (2014) Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407
35. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7):658–670
36. Melcher A et al (2011) Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19(6):1008–1016
37. Fueyo J et al (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652–660
38. Jiang H et al (2007) Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410–1414
39. Jiang H et al (2011) Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 85(10):4720–4729
40. Li Y et al (2008) Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 68(17):6889–6895
41. Uhl M et al (2009) Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ 16(7):991–1005
42. Heimberger AB, Sampson JH (2011) Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol 13(1):3–13
43. Carro MS et al (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279):318–325
44. Freije WA et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18):6503–6510
45. Murat A et al (2008) Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26(18):3015–3024
46. Suntharalingam G et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028
47. Wen PY et al (2010) Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 12(1):68–75
48. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697
49. Topalian SL et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030
50. Liao B et al (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589–593
51. Wikstrand CJ, Bigner DD (1981) Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells: production of reactive antisera and absence of EAE induction. J Neuroimmunol 1(3):249–260
52. Lammert A et al (2013) Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 121(10):581–587
53. Orgogozo JM et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46–54
54. Zitvogel L et al (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1):74–88
55. Kroemer G et al (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72